Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
PF-04620110 · 6 trials · 5 indications
Change from baseline in post-prandial area under the plasma glucose concentration time curve as determined by standardized MMTT. Linear trapezoidal method was used to compute AUC.
| Arm | Type | Description |
|---|---|---|
| PF-04620110 | EXPERIMENTAL | - |
| placebo | PLACEBO_COMPARATOR | - |
| ABCE, ACBD, BACD, BCAE, CABE and CBAD | EXPERIMENTAL | - |
| Placebo Comparator | PLACEBO_COMPARATOR | - |
| ABC, ACB, BAC, BCA, CAB, and CBA | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| PF-04620110 | DRUG | 5 mg of PF-04620110 given once daily |
| Placebo | DRUG | Matching placebo giving for 4 weeks |
Inclusion Criteria: * Male and/or female subjects between the ages of 18 and 60 years; * Body Mass Index (BMI) of \>25.0 kg/m2 and \<40 kg/m2; * Subjects must have a historical diagnosis of T2DM in accordance with the ADA guidelines; * Subjects who have been on well-tolerated and stable doses of me...
PF-04620110 is an investigational small molecule being developed by Pfizer, Inc. (PFE). It has been studied in Phase 1 clinical trials for conditions including obesity, overweight, healthy volunteers, and type 2 diabetes patients. It is not approved and remains in clinical development.
PF-04620110 has been investigated for use in obesity, overweight, and type 2 diabetes patients, as well as in healthy volunteers. It was studied in early-stage clinical trials to assess its safety, tolerability, and pharmacokinetics in these populations.
PF-04620110 is developed by Pfizer, Inc., a biopharmaceutical company traded on the New York Stock Exchange under the ticker symbol PFE. The company has sponsored Phase 1 clinical trials of this investigational small molecule.
PF-04620110 is in Phase 1 clinical development. All completed trials for this drug are Phase 1 studies. It is an investigational agent and has not received FDA approval for any indication.
PF-04620110 has been studied in four completed Phase 1 trials: NCT00959426 in overweight and obese healthy volunteers, NCT01064492 in healthy adults for bioavailability and food effect, NCT01166217 in healthy subjects, and NCT01298518 in type 2 diabetes patients. All trials are completed.
PF-04620110 is the primary identifier for this investigational compound. No alternative names have been reported in the clinical trial data. It is a small molecule developed by Pfizer, Inc. for potential metabolic indications.